BC
OPNT

Broadfin Capital’s Opiant Pharmaceuticals, Inc. Common Stock OPNT Stock Holding History

Broadfin Capital’s Portfolio OPNT Stock Details OPNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-85,484
Closed -$1.12M – 47
2019
Q1 		$1.12M Buy
+85,484
New +$1.25M 0.23% 41

Other funds holding OPNT

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Broadfin Capital's OPNT Position: Q2 2019 in Review

Broadfin Capital sold out of Opiant Pharmaceuticals, Inc. Common Stock (OPNT) in Q2 2019, closing a stake of 85,484 shares — an estimated $1.12M sold.

Broadfin Capital first reported a position in OPNT in Q1 2019 and held it in 1 quarter. The position peaked at $1.12M in Q1 2019. 15 funds tracked by Wall St. Rank hold OPNT as of Q2 2019.

  • Broadfin Capital reported no remaining Opiant Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Broadfin Capital sold 85,484 Opiant Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $1.12M.
  • Broadfin Capital first reported a position in Opiant Pharmaceuticals, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Broadfin Capital's Opiant Pharmaceuticals, Inc. Common Stock position peaked at $1.12M in Q1 2019.
  • 15 funds tracked by Wall St. Rank held Opiant Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.